ELVN Enliven Therapeutics Inc

Price (delayed)

$46.09

Market cap

$3.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.67

Enterprise value

$3.24B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 10
Highlights
ELVN's equity has soared by 97% QoQ and by 83% YoY
The company's quick ratio has surged by 96% YoY and by 61% QoQ
The company's net income fell by 7% QoQ and by 6% YoY

Key stats

What are the main financial stats of ELVN

ELVN stock price

How has the Enliven Therapeutics stock price performed over time
Intraday
-4.36%
1 week
-6.17%
1 month
-22.95%
1 year
140.18%
YTD
199.29%
QTD
-9.18%

Financial performance

How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$124.41M
Net income
-$105.93M
Gross margin
N/A
Net margin
N/A
Enliven Therapeutics's operating income has decreased by 9% YoY and by 7% QoQ
The company's net income fell by 7% QoQ and by 6% YoY

Price vs fundamentals

How does ELVN's price correlate with its fundamentals

Growth

What is Enliven Therapeutics's growth rate over time

Valuation

What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
3.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enliven Therapeutics's EPS has increased by 17% YoY
ELVN's equity has soared by 97% QoQ and by 83% YoY
ELVN's P/B is 37% above its 5-year quarterly average of 2.4

Efficiency

How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital is up by 46% year-on-year and by 16% since the previous quarter
The return on equity is up by 37% year-on-year and by 12% since the previous quarter
Enliven Therapeutics's ROA has increased by 35% YoY and by 11% from the previous quarter

Dividends

What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELVN.

Financial health

How did Enliven Therapeutics financials performed over time
The current ratio has soared by 97% YoY and by 59% from the previous quarter
Enliven Therapeutics's total assets has soared by 96% from the previous quarter and by 81% YoY
The debt is 100% less than the equity
ELVN's equity has soared by 97% QoQ and by 83% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.